20 august 2021 not yet covovax approved - - 200 million 28 december 2021 not yet sputnik light approved - - - 6 february 2022 not yet in september 2021, india's government announced that it would not buy covid-19 shots from pfizer (pfe.n)/biontech (22uay.de) and moderna (mrna.o), mainly because the domestic output of more affordable and easier-to-store vaccines of serum institute of india, bharat biotech & cadila healthcare has jumped. india will make 8 million doses of the johnson and johnson vaccine available by the end of october under the quad vaccine partnership. vaccines in trial stage vaccine type (technology) phase i phase ii phase iii no. of participants in clinical trial planned capacity bbv154 adenovirus vector (intranasal) completed in progress pending 175 100 million hgc019 mrna completed in progress pending 120 60 million global distribution of india-manufactured vaccines vaccine maitri (english: vaccine friendship) is a humanitarian initiative undertaken by the indian government to provide covid-19 vaccines to countries around the world. the government started providing vaccines from 20 january 2021. as of 6 march 2022, india had delivered around 16.3 cror doses of vaccines to 96 countries. of these, 1.43 cror doses were gifted to 46 countries by the government of india. the remaining 10.71 cror were supplied by the vaccine producer under its commercial and, 4.15 cror doses were supplied throw covax obligations. in late march 2021, the government of india temporarily froze exports of the covishield, citing india's own covid crisis and the domestic need for these vaccines. the health minister of india, mr. mansukh mandaviya announced in september that india will resume the export of vaccines from october to the rest of the world. countries that received doses of the indian-made covaxin as of 6 march 2021 200,000 doses of covid-19 vaccines were gifted by india to the un peacekeepers on 27 march to be distributed to all peacekeeping missions. vaccines india has two approved covid-19 vaccines: covishield and covaxin. both of them were exported and used in foreign grants by the government of india. covishield main article: oxford–astrazeneca covid-19 vaccine a vial of covishield, the indian-manufactured version of the astrazeneca vaccine. on 1 january 2021, the drug controller general of india, approved the emergency or conditional use of covishield. covishield is developed by the university of oxford and its spin-out company, vaccitech. covaxin main article: covaxin a vial of covaxin, india's first indigenous covid-19 vaccine by bharat biotech on 2 january 2021, covaxin india's first covid-19 vaccine, developed by bharat biotech in association with the indian council of medical research and national institute of virology received approval from the drug controller general of india for its emergency or conditional usage. vaccine supply india kicked off international shipment of the vaccines on 20 january 2021, only four days after starting its own vaccination program. bhutan and maldives were the first countries to receive vaccines as a grant by india. this was quickly followed by shipments to nepal, bangladesh, myanmar and seychelles. by mid-march 2021, india was also supplying vaccines on a commercial basis to countries including canada, the uk, and saudi arabia. as of 21 february 2022, india had exported total 16,29,63,500 doses including 1,42,67,000 vaccine provided as grant to more than 96 nations and, un peacekeepers and un health workers. the serum institute of india was selected as a key supplier of cost-effective covid-19 vaccines to the covax initiative, 19.8 million doses of covishield vaccines were supplied by india to various countries through the initiative. in may, when covax was already short 140 million doses, the serum institute announced that it expected to maintain its suspension of vaccine deliveries to covax through the end of 2021 due to the second wave of covid-19 in india and the us ban on export of key raw materials. international organizations imf: imf chief economist gita gopinath lauded india for playing a key role during the crisis by dispatching vaccines to many countries. she said "i also want to mention that india really stands out in terms of its vaccine policy. if you look at where exactly is one manufacturing hub for vaccines in the world – that will be india." countries jamaica of the oacps has thanked indian efforts in delivering vaccines to developing and least developed countries. nepal prime minister khadga prasad oli thanked india stating; "we got an early chance to administer the covid-19 vaccine. for this, i thank our neighbouring nation india, its government, the people, and especially prime minister narendra modi. they sent 10 lakh doses of vaccines to us as a grant within a week of the roll-out in india." st. lucia on behalf of caricom thanked india for providing vaccine supplies to them. barbados prime minister mia amor mottley thanked prime minister narendra modi for the supply of "made in india" covid-19 vaccines. she tweeted, "pm modi made it possible for more than 40,000 persons in barbados and tens of thousands elsewhere, to receive their 1st dose of covishield via vaccine maitri before receiving his. a genuine demonstration of generosity. thank you and we wish you continued good health." antigua and barbuda prime minister gaston browne had thanked prime minister of india narendra modi "for demonstrating an act of benevolence, kindness and empathy", for sending vaccines to caribbean countries. afghanistan afghanistan's ambassador to india farid mamundzay said "thank you, india for providing afghan people lifesaving gift on the first day of 2022!" leaders who received vaccines provided by india cambodia – heng samrin, say chhum nepal – kp sharma oli gallery covid-19 vaccine from india arrives at seychelles. delivery of covishield covid-19 vaccine from india to brazil. delivery of covishield covid-19 vaccine from india to brazil. vaccination drive for covid prevention in bhopal, india. vaccination rollout statistics by state or ut state/union territory population (2021 census projection) 1st dose 2nd dose precautionary/ booster dose cumulative doses administered percentage of people given one dose percentage of people fully vaccinated india 1,38,94,19,783 1,02,57,89,302 95,20,33,158 22,85,93,024 2,20,64,15,484 74% 69% andaman and nicobar islands 4,00,000 3,47,616 3,53,284 2,90,363 9,91,263 87% 88% andhra pradesh 5,27,87,000 4,47,04,006 4,75,78,542 1,86,73,709 11,09,56,257 85% 90% arunachal pradesh 15,33,000 9,61,347 8,21,814 1,41,357 19,24,518 63% 54% assam 3,50,43,000 2,48,12,811 2,21,46,472 33,70,486 5,03,29,769 71% 63% bihar 12,30,83,000 7,34,81,173 6,79,02,890 1,58,80,011 15,72,64,074 60% 55% chandigarh 12,08,000 11,85,483 9,88,149 1,13,952 22,87,584 98% 82% chhattisgarh 2,94,93,000 2,12,67,642 2,03,43,637 75,56,167 4,91,67,446 72% 69% dadra and nagar haveli 6,08,000 4,62,349 3,56,857 80,437 8,99,643 76% 59% daman and diu 4,09,000 3,19,979 2,80,074 79,977 6,80,030 78% 68% delhi 2,05,71,000 1,82,95,806 1,57,15,408 33,90,516 3,74,01,730 89% 76% goa 15,59,000 14,40,021 12,95,703 1,38,544 28,74,268 92% 83% gujarat 6,97,88,000 5,43,96,424 5,40,29,392 1,96,58,376 12,80,84,192 78% 77% haryana 2,94,83,000 2,36,78,004 1,98,37,948 19,93,858 4,55,09,810 80% 67% himachal pradesh 73,94,000 66,46,431 63,27,364 23,48,606 1,53,22,401 90% 86% jammu and kashmir 1,34,08,000 1,13,72,533 1,17,68,086 16,41,339 2,47,81,958 85% 88% jharkhand 3,84,71,000 2,39,67,125 1,78,51,928 20,38,403 4,38,57,456 62% 46% karnataka 6,68,45,000 5,51,73,853 5,53,90,664 1,15,80,517 12,21,45,034 83% 83% kerala 3,54,89,000 2,91,49,999 2,52,69,114 30,83,315 5,75,02,428 82% 71% ladakh 2,97,000 2,38,303 2,04,097 1,24,714 5,67,114 80% 69% lakshadweep 68,000 61,813 60,521 22,926 1,45,260 91% 89% madhya pradesh 8,45,16,000 6,07,49,230 5,92,31,988 1,39,55,836 13,39,37,054 72% 70% maharashtra 12,44,37,000 9,16,68,492 7,66,19,826 96,49,039 17,79,37,357 74% 62% manipur 31,65,000 16,49,406 13,39,146 2,80,404 32,68,956 52% 42% meghalaya 32,88,000 14,46,758 10,87,649 91,016 26,25,423 44% 33% mizoram 12,16,000 8,94,318 7,50,177 1,48,803 17,93,298 74% 62% nagaland 21,92,000 9,23,844 7,44,853 70,898 17,39,595 42% 34% odisha 4,56,96,000 3,52,50,660 3,30,11,967 1,32,82,350 8,15,44,977 77% 72% puducherry 15,71,000 9,94,613 8,68,099 4,11,347 22,74,059 63% 55% punjab 3,03,39,000 2,41,61,300 2,09,93,294 18,88,564 4,70,43,158 80% 69% rajasthan 7,92,81,000 5,70,33,302 5,10,28,962 76,28,646 11,56,90,910 72% 64% sikkim 6,77,000 5,91,875 5,54,656 2,13,916 13,60,447 87% 82% tamil nadu 7,64,02,000 6,12,13,217 5,72,16,684 90,89,575 12,75,19,476 80% 75% telangana 3,77,25,000 3,24,46,658 3,15,58,188 1,35,45,844 7,75,50,690 86% 84% tripura 40,71,000 29,16,816 25,23,858 4,78,322 59,18,996 72% 62% uttar pradesh 23,09,07,000 17,69,98,255 16,89,68,355 4,60,35,998 39,20,02,608 77% 73% uttarakhand 1,13,99,000 91,18,200 87,30,370 22,85,740 2,01,34,310 80% 77% west bengal 9,81,25,000 7,35,26,540 6,67,04,028 1,58,55,654 15,60,86,222 75% 68% miscellaneous — 22,43,100 15,79,114 14,73,499 52,95,713 — — as of march 4, 2023 7:00 am ist as of march 4, 2023, populations above the age of 12 are only eligible for vaccination. the percentage of population inoculated shown in the table above is according to the 2021 projected population of india with all age groups. according to the government, based on the projected mid-year count for 2021, the country's total population aged 12 years and above is approximately 108 crore. around 94.61% of the 12+ population of the country have received at least one dose of the covid-19 vaccine since the vaccination drive began. in addition to this, 87.81% of the eligible population has been fully vaccinated. vaccine acceptance in india over 80% of the population of india have a positive response for getting anti covid shots. india has one of the lowest vaccine hesitancy in the world. there was vaccine hesitancy in the initial months of 2021, especially in rural india and among poor and tribal populations. constant government and public awareness drastically reduced vaccine hesitancy. since may 2021, more than half of daily doses administered in india have been from rural parts. vaccine centers in india have witnessed large number of people willing to get covid vaccine resulting in overcrowding and mismanagement. many centers across india in months of april & may reported severe shortage of covid vaccines due to large crowds turning up for vaccination. in cities like mumbai, new delhi, bengaluru many people even after waiting for hours did not receive their covid vaccine due to shortage. since july, vaccine supply has drastically increased thus india is vaccinating at a very fast pace. one study published on vaccine acceptance shows that 79.5% of people from delhi want to take a covid-19 vaccine. in another study which was published from west bengal, a state in eastern india, has shown that 77.27% of people want to take the covid-19 vaccine. according to the finding from these two studies, it can be expected that over 75% of people want to get a covid-19 vaccine. uttar pradesh achieved 100% first dose saturation in covid-19 vaccination, with over 26 crore doses administered, highest in india. the entire eligible population received the first dose by monday evening. nearly 70% of adult population fully vaccinated. health teams praised for administering over 7 crore doses in january. adverse events like many other vaccinations, covid-19 vaccines also have a risk of causing side effects. according to india's union ministry of health and family welfare, the most common side-effects include pain or swelling at the injection site, fever, irritability and headaches. the uk government also lists fatigue, nausea and joint pain as common side-effects of the oxford vaccine (known as covishield in india). medical experts maintain that vaccines used are safe and their benefits outweigh the risks. it is also important to note that adverse cases do not necessarily have a causal relationship with the vaccines. a total of 617 serious adverse events were reported until march 29. of these, 180 cases resulted in death. the immunisation technical support unit at the federal health ministry examined 192,000 case reports, including 12,400 deaths. in more than half of the examined cases of death, the cause of death was found to be acute coronary syndrome. however, the documentation had been completed for only 3,500 cases. by 7 june, 26,000 adverse events had been reported following immunisation. of this, 24,901 were minor, 412 were significant and 887 were serious. 488 deaths were also reported, including 301 men and 178 women (details of 9 deaths were not available). both vaccines had an adverse reaction rate of about 0.01% and a fatality rate of around 0.0001% - 24,703 events and 457 deaths from 210 million covishield doses, 1,497 events and 20 deaths following 25 million covaxin doses. maharashtra reported the most adverse events (4,521), followed by kerala (4,074), karnataka (2,650) and west bengal (1,456). on 15 june, the government published a review of case reports that had occurred between 5 february and 31 march 2021, focusing on 31 cases and one death from anaphylaxis that were believed to have been attributed to the vaccine, out of nearly 60 million doses administered in the time period. only three of these cases, and the single death of a 68-year-old patient, were determined to be "vaccine-product related", with the remainder having been classified as coincidental, indeterminate, or unclassifiable. the report stated that "mere reporting of